# OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

> **NCT00105937** · PHASE3 · COMPLETED · sponsor: **Cephalon** · enrollment: 300 (—)

## Conditions studied

- Pain
- Cancer

## Interventions

- **DRUG:** OraVescent fentanyl citrate

## Key facts

- **NCT ID:** NCT00105937
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 300 (—)
- **Last updated:** 2012-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105937, "OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00105937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*